According to Gram Research analysis, Babaodan, a traditional Chinese herbal formula, reduces fatty liver disease by activating protective proteins (FXR and SLC22A7) and suppressing inflammation through NF-κB pathways. In laboratory studies, the formula normalized 17 of 24 abnormal blood chemicals associated with fatty liver disease and reduced fat buildup in liver cells in a dose-dependent manner, though human clinical trials are still needed to confirm these benefits.
Researchers studied Babaodan, a traditional Chinese medicine used for centuries to treat liver problems, to understand how it works against fatty liver disease caused by poor diet and metabolism. Using advanced laboratory techniques, scientists discovered that the formula works by fixing how the liver handles bile acids and reducing inflammation. The study involved testing the medicine in liver cells and mice with diet-induced fatty liver disease. Results showed that Babaodan activated protective proteins in liver cells, reduced fat buildup, and normalized harmful chemicals in the blood. This research provides scientific evidence supporting why this ancient formula has been used in Chinese medicine for liver health.
Key Statistics
A 2026 laboratory study found that Babaodan normalized 17 out of 24 metabolites associated with metabolic dysfunction-associated steatotic liver disease, with bile acid biosynthesis being the most restored pathway.
Research published in the Journal of Ethnopharmacology showed that Babaodan dose-dependently reduced hepatocyte steatosis, apoptosis, and inflammation through coordinated regulation of FXR, NF-κB p65 phosphorylation, and SLC22A7 protein expression.
A multi-omics analysis identified SLC22A7 as a central hub protein correlated with bilirubin, insulin, and inflammatory mediators in fatty liver disease, with Babaodan treatment upregulating this key transporter protein.
The Quick Take
- What they studied: How an ancient Chinese herbal formula called Babaodan helps treat metabolic dysfunction-associated steatotic liver disease (fatty liver disease caused by poor metabolism and diet)
- Who participated: Laboratory studies using liver cells from mice and mice fed a high-fat diet to mimic human fatty liver disease
- Key finding: Babaodan reduced fat buildup in liver cells, decreased inflammation, and normalized 17 out of 24 harmful blood chemicals associated with fatty liver disease by activating protective proteins
- What it means for you: This research suggests Babaodan may help treat fatty liver disease by working on multiple targets in the body simultaneously, though human clinical trials are still needed to confirm safety and effectiveness
The Research Details
Scientists used a multi-omics approach, which means they examined the problem from multiple angles using different advanced technologies. They studied individual liver cells from mice with fatty liver disease to see which cells were most affected and which genes were turned on or off. They also analyzed blood samples to identify chemical changes associated with the disease, and examined liver proteins involved in bile acid handling—the liver’s natural detoxification process. The researchers then tested Babaodan in isolated liver cells treated with palmitic acid (a fatty substance) and in mice fed a high-fat diet to see if the formula could reverse the damage.
This multi-angle approach allowed researchers to understand not just whether Babaodan worked, but exactly how it worked at the molecular level. They used Western blotting (a technique to measure protein levels) and biochemical assays (chemical tests) to measure specific molecules involved in inflammation and bile acid metabolism.
This research approach is important because fatty liver disease is complex—it involves multiple broken systems in the body at the same time. By studying the problem from multiple angles (genes, proteins, and blood chemicals), researchers could identify the key mechanisms that Babaodan targets. This helps explain why traditional medicines often work better than single-target drugs and provides a scientific framework for how ancient formulas can be validated and improved.
The study used sophisticated modern laboratory techniques (single-cell transcriptomics, untargeted metabolomics, and targeted proteomics) that provide detailed molecular-level data. Testing was performed in both isolated cells and living animals, which strengthens confidence in the findings. However, the study was conducted in laboratory and animal models only—human clinical trials would be needed to confirm these results apply to people. The research was published in the Journal of Ethnopharmacology, a peer-reviewed scientific journal focused on traditional medicine research.
What the Results Show
Babaodan significantly reduced fat accumulation in liver cells in a dose-dependent manner, meaning higher doses had stronger effects. The formula also reduced cell death (apoptosis) and suppressed inflammatory signals in liver cells. When researchers analyzed blood samples from treated mice, they found that Babaodan normalized 17 out of 24 metabolites (chemical compounds) that are abnormally elevated in fatty liver disease. The most important pathway that was restored was bile acid biosynthesis—the liver’s natural process for making bile acids that help digest fats and remove toxins.
At the molecular level, Babaodan worked by activating a protein called FXR (farnesoid X receptor), which acts as a master switch for bile acid metabolism. The formula also suppressed NF-κB p65 phosphorylation, which is a key step in the inflammatory cascade that damages liver cells. Additionally, Babaodan increased levels of a protein called SLC22A7, which is responsible for transporting bile acids and other compounds out of liver cells.
These three mechanisms—FXR activation, NF-κB suppression, and SLC22A7 upregulation—appeared to work together as an interconnected system. Network analysis showed that SLC22A7 was a central hub connected to multiple important markers including bilirubin (a bile pigment), insulin (a blood sugar hormone), and inflammatory mediators (molecules that trigger inflammation).
The study identified hepatocytes (the main liver cells) as the principal location where bile acid disruption and inflammation accumulate in fatty liver disease. This finding helps explain why the liver is so vulnerable to metabolic dysfunction. The research also showed that IL-6, a major inflammatory molecule, was significantly reduced by Babaodan treatment, suggesting the formula has anti-inflammatory effects beyond just fixing bile acid problems. The coordinated regulation of multiple bile secretion-related proteins indicates that Babaodan works on the entire bile acid handling system rather than just one component.
This research builds on decades of clinical use of Babaodan in China for liver disorders by providing the first detailed molecular explanation of how it works. Previous studies of traditional Chinese medicines for fatty liver disease have often focused on single targets or single pathways. This study’s multi-target approach aligns with modern understanding that complex diseases like fatty liver disease require multi-target treatments. The findings support why combination herbal formulas, which contain multiple active compounds, may be more effective than single isolated compounds.
This study was conducted entirely in laboratory settings and animal models—the results have not yet been tested in humans. Animal studies don’t always translate to human results due to differences in metabolism and physiology. The exact sample size for animal experiments was not specified in the abstract. The study focused on identifying mechanisms but did not compare Babaodan directly to existing fatty liver disease treatments, so we don’t know if it’s more or less effective than current options. Additionally, the specific active compounds in Babaodan responsible for the effects were not identified, which limits understanding of how to optimize the formula.
The Bottom Line
Based on this research, Babaodan shows promise as a potential treatment for metabolic dysfunction-associated steatotic liver disease through multiple mechanisms. However, confidence in these findings is moderate because the research is limited to laboratory and animal studies. Before anyone should consider using Babaodan, human clinical trials are needed to confirm safety, determine appropriate doses, and verify that the benefits seen in animals translate to people. People with fatty liver disease should continue following established treatments (weight loss, exercise, dietary changes) while this research progresses toward human testing.
This research is most relevant to people with metabolic dysfunction-associated steatotic liver disease (fatty liver disease), their healthcare providers, and researchers studying traditional medicine. People with obesity, type 2 diabetes, or metabolic syndrome should be aware of this research as they have higher risk for fatty liver disease. Healthcare providers in China and other countries using traditional Chinese medicine may find this research useful for understanding how Babaodan works. This research is less immediately relevant to people without liver disease, though it may eventually lead to preventive applications.
In the animal studies presented here, Babaodan showed effects relatively quickly, but the exact timeline wasn’t specified. If human clinical trials proceed, it typically takes 3-5 years to complete Phase 2 trials (which test safety and effectiveness) and another 2-3 years for Phase 3 trials (which confirm benefits in larger populations). Even if Babaodan proves effective in humans, realistic expectations would be gradual improvement over weeks to months rather than immediate results. Fatty liver disease develops over years, so reversing it typically requires sustained treatment.
Frequently Asked Questions
How does Babaodan help with fatty liver disease?
Babaodan works through three interconnected mechanisms: it activates FXR (a master switch for bile acid metabolism), suppresses NF-κB inflammation pathways, and increases SLC22A7 (a protein that removes bile acids from liver cells). Together, these actions reduce fat buildup and inflammation in the liver.
Is Babaodan proven to work in humans?
Current research shows Babaodan works in laboratory cells and mice with fatty liver disease, but human clinical trials have not yet been completed. More research is needed before recommending it as a standard treatment for people with fatty liver disease.
What is metabolic dysfunction-associated steatotic liver disease?
This is fatty liver disease caused by poor metabolism and diet, often linked to obesity, type 2 diabetes, and metabolic syndrome. Fat accumulates in liver cells, causing inflammation and potentially leading to liver damage if untreated.
Can I use Babaodan instead of losing weight and exercising?
No. Weight loss, exercise, and dietary improvements remain the foundation of fatty liver disease treatment. Babaodan may eventually complement these lifestyle changes, but it should not replace them. Always consult your doctor before using any supplement.
How long would it take to see results from Babaodan?
The animal studies didn’t specify exact timelines, but fatty liver disease develops over years, so treatment typically requires sustained effort over weeks to months. Individual results vary, and medical supervision is essential to monitor progress.
Want to Apply This Research?
- Track liver health markers monthly: measure weight, waist circumference, and if possible, liver enzyme levels (ALT and AST) through blood tests. Also monitor energy levels and digestive symptoms, as these often improve with liver health improvements.
- If considering Babaodan as part of a treatment plan, use the app to log daily doses and track concurrent lifestyle changes (diet improvements, exercise minutes, alcohol consumption). This helps identify which combination of interventions produces the best results for your individual situation.
- Set monthly reminders for liver function blood tests if available. Track weight and symptoms weekly. Create a dashboard showing trends in liver health markers over 3-6 months to visualize whether the treatment is working. Share this data with your healthcare provider to guide ongoing treatment decisions.
This article summarizes laboratory and animal research on Babaodan for fatty liver disease. These findings have not been tested in humans, and Babaodan is not approved by the FDA for treating any disease in the United States. Do not use Babaodan or any supplement to replace established medical treatments without consulting your healthcare provider. If you have fatty liver disease or metabolic dysfunction, work with a qualified physician to develop a comprehensive treatment plan including lifestyle modifications. The information in this article is for educational purposes only and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.